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Summary
Opioid and tachykinin systems are involved in modu-
lation of pain transmission in the spinal cord. Regu-
lation of surface opioid receptors on nociceptive
afferents is critical for opioid analgesia. Plasma-mem-
brane insertion of -opioid receptors (DORs) is in-
duced by stimulus-triggered exocytosis of DOR-con-
taining large dense-core vesicles (LDCVs), but how
DORs become sorted into the regulated secretory path-
way is unknown. Here we report that direct interaction
between protachykinin and DOR is responsible for sort-
ing of DORs into LDCVs, allowing stimulus-induced
surface insertion of DORs and DOR-mediated spinal
analgesia. This interaction is mediated by the sub-
stance P domain of protachykinin and the third lu-
minal domain of DOR. Furthermore, deletion of the
preprotachykinin A gene reduced stimulus-induced
surface insertion of DORs and abolished DOR-medi-
ated spinal analgesia and morphine tolerance. Thus,
protachykinin is essential for modulation of the sensi-
tivity of nociceptive afferents to opioids, and the opi-
oid and tachykinin systems are directly linked by pro-
tachykinin/DOR interaction.*Correspondence: xu.zhang@ion.ac.cn
7 These authors contributed equally to this work.Introduction
The opioid system serves inhibitory functions in pain
transmission. δ- and -opioid receptors, homologous
G protein-coupled receptors (Evans et al., 1992; Kieffer
et al., 1992; Thompson et al., 1993), are expressed in
small dorsal root ganglion (DRG) neurons and mediate
the effects of endogenous opioid peptides and analge-
sics. Interestingly, while -opioid receptors (MORs) are
transported along the constitutive pathway (Zhang et
al., 1998a), δ-opioid receptors (DORs) are sorted into
the regulated pathway and are often found to be asso-
ciated with large dense-core vesicles (LDCVs; Cheng
et al., 1995; Zhang et al., 1998b), secretory granules
with electron-opaque content. Furthermore, plasma-
membrane insertion of DORs can be triggered by DOR-
agonist-induced or nociceptive stimulus-induced Ca2+
influx that causes exocytosis of LDCVs (Bao et al.,
2003), consistent with the presence of DORs in the reg-
ulatory pathway. Since newly synthesized cell-surface
receptors are in general sorted into microvesicles of the
constitutive pathway and inserted into the plasma
membrane by spontaneous exocytosis, some cellular
mechanisms must be present to sort DORs into LDCVs
for regulated surface insertion.
Sorting signals have been identified for some mem-
brane proteins of secretory granules, such as that
found in the cytoplasmic domain of P-selectin (Disdier
et al., 1992). Although it has long been suggested that
granule membrane proteins may be sorted to the gran-
ules by binding of their luminal domains to the granule
content (Arvan and Castle, 1998; Kelly, 1985), there is
no direct evidence in support of this idea. In the present
study, we investigated whether the sorting of DORs into
LDCVs is due to the interaction with the granular
content and found that direct binding of DOR with sub-
stance P-containing protachykinin, a content protein of
LDCVs in small DRG neurons, is essential for the sorting.
Substance P is the first pronociceptive neuropeptide
identified in small DRG neurons. Together with other
tachykinin peptides, it is coded by the preprotachykinin
A (PPT-A) gene (Chiwakata et al., 1991; Nawa et al.,
1983). Differential RNA splicing of primary PPT-A tran-
scripts results in the production of three substance
P-encoding mRNAs, α-, β-, and γ-PPT mRNAs, among
which β-PPT (the precursor for both substance P and
substance K) is expressed in small DRG neurons (Helke
et al., 1990; Hökfelt et al., 1975). Cleavage of the signal
peptide from β-PPT in the endoplasmic reticulum yields
protachykinin, which is transported to the trans-Golgi
network, where it is sorted into LDCVs. Protachykinin
undergoes further cleavage and other processing events
within LDCVs to produce substance P and other mature
peptides while LDCVs are being transported to the
nerve terminals for secretion.
Small DRG neurons give rise to unmyelinated noci-
ceptive afferents (C fibers). Substance P is transported
to the peripheral and central terminals of C fibers and
released after tissue damage or in response to nocicep-
tive stimuli. Peripherally released substance P contributes
Cell
620to enhanced pain sensation indirectly via its proinflamma-
tory effects, including vasodilatation and histamine re-
lease from mast cells (Helke et al., 1990; Woolf and Salter,
2000). Substance P released from the central terminals
acts on dorsal spinal-cord neurons expressing the sub-
stance P/neurokinin 1 receptor (Mantyh et al., 1995;
Woolf and Salter, 2000). However, the precise role of
tachykinins in the nociceptive response of the spinal
cord remains controversial because substance P-recep-
tor antagonists cannot reduce human pain (Rupniak
and Kramer, 1999), and the nociceptive defect in
PPT-A knockout mice appears to be mainly involved in
supraspinal mechanisms and peripheral proinflamma-
tory effects (Cao et al., 1998; Zimmer et al., 1998). In
this study, we found that protachykinin directly in-
teracts with DOR and that this interaction is responsi-
ble for sorting DORs into LDCVs. This novel action of
protachykinin allows regulated insertion of DORs in C fi-
bers upon nociceptive stimulation, enabling DOR-medi-
ated spinal analgesia.
Results
DOR Localization in LDCVs Requires
Preprotachykinin A Expression
The first clue to the mechanism of the LDCV localiza-
tion of DORs came from the observation that DORs are
always found to colocalize with substance P in a sub-
population of small DRG neurons. In mouse DRG, DOR
is expressed in about half of the cells (Bao et al., 2003),
most of which are small neurons. In the subpopulation
(w41%) of DOR-immunoreactive small neurons that
contained substance P, DORs were consistently found
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pFigure 1. Requirement of Preprotachykinin A
Expression for LDCV Localization of DOR in
Small DRG Neurons
(A) Double-immunofluorescence labeling
shows colocalization of DOR (in green) and
substance P (SP, in red) in LDCVs in small
DRG neurons of the mouse. Pre-embedding
immunogold-silver labeling of DOR com-
bined with postembedding immunogold (10
nm in diameter) labeling of substance P
shows localization of DOR (arrowhead) in the
membrane of LDCV and substance P (arrow)
in the lumen of LDCV. Quantitative analysis
at the ultrastructural level shows that the
LDCVs carrying DOR almost exclusively con-
tain substance P (a total of 180 LDCVs in
three experiments). Data are represented as
mean ± SEM.
(B) Double-immunofluorescence labeling
shows that DOR (in green) and CGRP (in red)
are colocalized in LDCVs in small DRG neu-
rons of wild-type (+/+) mice but not in LDCVs
of PPT-A knockout (−/−) mice. The number
of CGRP-containing vesicles in small DRG
neurons of PPT-A knockout mice is un-
changed (for both +/+ and −/− neurons, w7
LDCVs/m2 in the optic section through the
center of neuron).
(C) In small DRG neurons of PPT-A knockout
mice, immunogold-silver labeling of DOR is
seen in multivesicular bodies (arrowhead) instead of in LDCVs (mean ± SEM, n = 18 neuron profiles). **p < 0.01 versus the neurons of wild-
type mice. Postembedding immunogold labeling shows that, in small DRG neurons of PPT-A knockout mice, CGRP is still localized in
LDCVs (arrowhead).
Scale bars, 5 m for confocal images; 100 nm for electron micrographs.in distinct substance P-containing LDCVs (Figure 1A).n contrast, in those neurons (w59%) that did not con-
ain substance P, DORs were found to be more diffusely
istributed in the cytoplasm, some localized to vesicu-
ar structures (Figure S1A).
Further indication that PPT-A expression is important
or the LDCV localization of DOR was provided by the
inding that, in PPT-A knockout mice, DOR was absent
n LDCVs. In wild-type small DRG neurons (n = 20),
3% ± 5% of DOR-immunoreactive LDCVs contained
alcitonin gene-related peptide (CGRP), a neuropeptide
hat normally colocalizes with substance P in LDCVs
Zhang et al., 1995). In contrast, we found that DOR and
GRP were present in different vesicular compartments
n small DRG neurons of PPT-A knockout mice (Figure
B). Ultrastructural study showed that DORs were lo-
alized in multivesicular bodies that are known to be
ysosomal compartments (Smith and Farquhar, 1966),
uggesting that DORs excluded from LDCVs are pro-
essed for degradation (Figure 1C). This abnormal DOR
ocalization in small DRG neurons of PPT-A knockout
ice was DOR specific since the CGRP localization
as unaffected (Figure 1C). It was also not caused by
ny change in DOR expression since the mRNA and
rotein level of DOR and the percentage of DOR-con-
aining DRG neurons (w54%) were similar to those
ound in wild-type mice (Figures S1B–S1D).
rotachykinin Is Sufficient for Sorting
OR into LDCV
aving found that PPT-A expression is necessary for
OR sorting into LDCVs, we further inquired whether
rotachykinin is sufficient for the sorting process. Theβ-preprotachykinin protein (1–130 amino acid residues)
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621(β-PPT(1–130)) contains the domains for potential sig-
nal peptide (1–19), N-terminal propeptide (20–57), sub-
stance P (58–68), and substance K (98–107) (Chiwakata
et al., 1991; Helke et al., 1990). In order to dissect the
domain of β-PPT involved in the DOR sorting, we used
human embryonic kidney 293 (HEK293) cells that do
not contain LDCVs or express DOR and tachykinin.
Transfection with the vector expressing chromogranin
A, a major gene for LDCV biogenesis (Kim et al., 2001),
induced LDCV-like vesicles in these cells. Further trans-
fection of the cell with the vector expressing DOR
tagged with a hemagglutinin (HA) epitope at the N ter-
minus did not result in DOR localization in chro-
mogranin A-induced vesicles (Figures 2A and 2B). In
contrast, coexpression of β-PPT(1–130) or β-PPT(1–68)
together with DOR resulted in localization of not only
substance P but also DOR in chromogranin A-induced
vesicles, as shown by immunostaining (Figures 2C–2E
and 2G; see Figure S2A for confocal images of Figure
2E in separated channels) and at the ultrastructural
level (Figure 2H). Interestingly, coexpression of MOR
with β-PPT(1–130) or β-PPT(1–68) did not result in MOR
localization to these vesicles (data not shown). The
vesicular localization of DORs was not due to the inter-
nalization of surface receptors since pulse-labeled sur-
face DORs were not found in chromogranin A-induced
tachykinin-containing vesicles (Figure S2B). These re-
sults support the notion that protachykinin is sufficient
for sorting DORs to LDCVs.
As shown earlier, DORs failed to be sorted to CGRP-
containing LDCVs in small DRG neurons of PPT-A
knockout mice (see Figure 1B). However, we found that
sorting of DORs into LDCVs was reinstated by express-
ing β-PPT(1–68) in these cultured DRG neurons from
PPT-A knockout mice (Figure 2I), consistent with the
results obtained using HEK293 cells.
The Substance P Domain of Protachykinin
Conveys DOR Sorting Signal
In order to further dissect the function of various do-
mains within β-PPT(1–68) for DOR sorting, we carried
out deletion and domain-swap experiments (Figure 2C).
As shown in Figures 2F and 2G, expression of the trun-
cated β-PPT missing the substance P domain (β-PPT
(1–57, 69–130)) in HEK293 cells failed to induce DOR
localization in chromogranin A-induced vesicles (see
Figure S2C for confocal images of Figure 2F in sepa-
rated channels). These results indicate that the sub-
stance P domain (β-PPT(58–68)) is essential for DOR
sorting. This notion was further supported by domain-
swap experiments. In HEK293 cells expressing exoge-
nous α-CGRP (1–119), which contains the domains for
signal peptide (1–25), propeptide (26–80), and CGRP
(83–119), coexpressed DORs were not found in chro-
mogranin A-induced vesicles (Figures 2C and 2G).
However, when the CGRP domain (83–119) was substi-
tuted with the substance P domain, DORs became lo-
calized in chromogranin A-induced vesicles (Figures 2C
and 2G). Thus, the substance P domain is sufficient for
conveying the localization signal to DOR, although it
must act as part of a larger peptide backbone, which
can be provided by either β-PPT(1–57) or α-CGRP (1–82).The Substance P Domain of Protachykinin
Interacts with DOR
To further investigate the mechanism underlying pro-
tachykinin-mediated DOR sorting, we examined whether
there is any interaction between DOR and the sub-
stance P domain. In experiments using HEK293 cells
coexpressing substance P [β-PPT(58–68)] fused with
green fluorescent protein (GFP) in the cytoplasm and
HA-DOR in the cell membrane, we found that HA-DOR
coimmunoprecipitated (CoIP) with substance P in the
cell lysate (Figures 3A and 3B). Neither expressed
CGRP-GFP nor neuropeptide Y-GFP CoIP with HA-
DOR (Figure 3A and data not shown). Whether endoge-
nous DOR in neurosecretory cells interacts with the
substance P domain was further examined in pheo-
chromocytoma (PC12) cells and in mouse DRG neu-
rons. Similar to small DRG neurons, PC12 cells con-
tained LDCVs, and endogenous DORs were colocalized
with substance P in LDCVs (Figure 3C). We applied the
membrane-permeable crosslinker disuccinimidyl su-
berate in PC12 cells and in dissociated DRG neurons
and found that endogenous DOR CoIP with substance
P (Figures 3C and 3D). These findings suggest that
DOR interacts with the substance P domain of pro-
tachykinin.
The Third Luminal Domain of DOR Is Responsible
for Sorting DOR to LDCV
The domain of DOR responsible for its LDCV localiza-
tion was further investigated by domain swap between
DOR and MOR. When expressed in PC12 cells, DOR
was found in LDCVs (Figures 4A and 4C; see Figure
S3A for immunostaining data), but MOR exhibited dif-
fuse distribution in the cytoplasm and high-level ex-
pression on the cell surface without the LDCV localiza-
tion (Figures 4A and 4D). Domain-swap experiments
showed that the third luminal domain of DOR (285–293)
was critical for the LDCV localization in transfected
PC12 cells (DOR M1–M3, Figures 4A–4C; see Figure
S3A for immunostaining data). Furthermore, when the
negatively charged aspartates 288 and 293 located
within this domain were mutated to noncharged alanine
(DOR(D288A, D293A), M4), the LDCV localization of
DOR was totally abolished (Figures 4A–4C), whereas
single mutation at either one of these two sites partially
attenuated the LDCV localization (M5 and M6, Figures
4A and 4C; see Figure S3A for immunostaining data). In
contrast, mutation of two positively charged arginines
(R291 and R292) to alanines within this domain did not
affect DOR localization (M7, Figures 4A and 4C). There-
fore, D288 and D293 appear to be essential for DOR
sorting.
To further examine whether the third luminal domain
of DOR (285–293) is sufficient for the LDCV localization,
we replaced a 9 amino acid sequence in the third extra-
cellular domain of MOR or neuropeptide Y Y1 receptor
(Eva et al., 1990) with DOR(285–293). We found that ex-
pression of this mutated MOR and neuropeptide Y Y1
receptor in PC12 cells resulted in localization of these
receptor proteins to LDCVs (Figures 4A and 4D; see
Figure S3B for data on Y1 receptor), suggesting that
the signal provided by DOR(285–293) is sufficient for
the LDCV localization in PC12 cells. The specificity of
this sorting signal is further supported by the finding
Cell
622Figure 2. Essential Role of Protachykinin in Biogenesis of DOR-Containing LDCV
In HEK293 cells, vectors expressing HA-tagged DOR (HA-DOR), chromogranin A (CgA), and wild-type or mutated β-preprotachykinin (β-PPT)
or α-CGRP are transfected in various combinations (A–G). Transfected cells are immunofluorescence stained and examined in confocal
microscope. HA-DOR is labeled with HA antibody. Scale bar, 10 m for (A), (B), and (D)–(F).
(A) In cells expressing HA-DOR, DOR is localized on the cell surface and in the cytoplasm.
(B) In the cell expressing chromogranin A-GFP and HA-DOR, DOR (in red) is not localized in chromogranin A (in green) vesicles (arrowhead).
(C) Diagram showing wild-type (WT) or mutants (M) of β-PPT and α-CGRP proteins. SP, substance P; SK, substance K.
(D) In the cell expressing chromogranin A-GFP and β-PPT(1–68) (β-PPT M1) with the domains of signal peptide, N-terminal propeptide, and
substance P, substance P (in red) is localized in chromogranin A (in green) vesicles (arrowhead). Substance P is labeled with its antibody.
(E) In the cell expressing HA-DOR, chromogranin A-GFP, and β-PPT(1–68), DORs (in red), substance P (in blue), and chromogranin A (in green)
are colocalized in vesicles (arrowhead, in white) (see Figure S2A for images of separated channels and the analysis of colocalization).
(F) In the cell expressing HA-DOR, chromogranin A tagged with c-Myc epitope, and β-PPT(1–57, 69–130)-GFP (β-PPT M2) missing the
substance P domain, DOR (in red) is not localized in β-PPT(1–57, 69–130) (in green) and chromogranin A (in blue) containing vesicles (arrow-
head, in cyan) (see Figure S2C for images of separated channels). Chromogranin A-Myc is labeled with c-Myc antibody.
(G) Quantitative analysis shows that, in HEK293 cells coexpressing DOR, chromogranin A, and β-PPT(1–130) or β-PPT(1–68) or α-CGRP(1–
82)/β-PPT(58–68) (α-CGRP M2), DOR is localized in chromogranin A vesicles. **p < 0.01 versus the cell coexpressing DOR and chromogranin
A (mean ± SEM, n = 30 cells/group).
(H) Pre-embedding immunogold-silver labeling with HA antibody shows that, in cells triple-transfected with vectors expressing HA-DOR,
β-PPT(1–68), and chromogranin A-GFP, DORs (arrowhead) associate with the membrane of LDCVs. **p < 0.01 versus the cells transfected
with HA-DOR (mean ± SEM, 12 cells/group). n.d., not detected. Scale bar, 100 nm.
(I) Double-immunofluorescence labeling shows that, in a cultured small DRG neuron of the newborn PPT-A knockout (−/−) mice, the colocali-
zation of DOR and CGRP in LDCVs (arrows) is rescued by the transfection with the vector expressing β-PPT(1–68)-GFP. **p < 0.01 (mean ±
SEM, n = 12 neuron profiles/group). Scale bar, 5 m.
Sorting of δ-Opioid Receptors
623Figure 3. Interaction between DOR and Substance P Domain of Protachykinin
(A) Coimmunoprecipitation (IP) and immunoblotting (IB) show that, in HEK293 cells cotransfected with vectors expressing β-PPT(58–68)-GFP
and HA-DOR, β-PPT(58–68)-GFP (w30 kDa) is found in HA-antibody-precipitated proteins. This interaction is inhibited by adding 1 M
substance P into the lysate. In cells cotransfected with vectors expressing HA-DOR and α-CGRP(83–119)-GFP (w33 kDa), no significant CoIP
signal of CGRP-GFP is detected. **p < 0.01, lanes 3 and 4 versus lanes 1 and/or 2 (mean ± SEM, n = 3).
(B) In HEK293 cells cotransfected with vectors expressing β-PPT(58–68)-GFP and HA-DOR, HA-DOR (w60 kDa) is identified in GFP-antibody-
precipitated proteins. **p < 0.01, lane 2 versus lane 1 (mean ± SEM, n = 3).
(C) Double-immunofluorescence labeling shows colocalization of DOR and substance P in LDCVs in PC12 cells. After crosslinking with
membrane-permeable disuccinimidyl suberate, in DOR-antibody-precipitated proteins, the substance P-immunoreactive band is seen at the
same position where the DOR band (w60 kDa) is found, while CGRP is not detected. In substance P-antibody-precipitated proteins, DOR is
also detected. The data represent three independent experiments. Scale bar, 5 m.
(D) After crosslinking with membrane-permeable disuccinimidyl suberate in dissociated mouse DRG neurons, immunoblot of substance P is
seen in DOR-antibody-precipitated proteins. The data represent three independent experiments.
Cell
624Figure 4. Identification of the Sorting Domain of DOR
(A) Diagram shows wild-type (WT) and mutants (M) of DOR and MOR and summarizes the results of the localization of these molecules
tagged with HA in transfected PC12 cells based on immunofluorescence labeling with HA antibody. Domain swap between DOR and MOR
(DOR M1–M3; MOR M1) shows that the third luminal (extracellular) domain of DOR (285–293) is responsible for the LDCV localization. Point
mutation of DOR (DOR M4–M7) indicates that D288 and D293 are critical for LDCV localization. TM, transmembrane domain; −, not in LDCVs;
++, mainly in LDCVs; +, in some LDCVs.
(B) Representative confocal images show the LDCV localization of the DOR mutant with DOR(1–262) replaced by MOR(1–282) (DOR M1). The
DOR with point mutation at D288 and D293 (DOR M4) is not localized in vesicles. Scale bar, 5 m.
(C) Pre-embedding immunogold-silver labeling with HA antibody in transfected PC12 cells shows that DOR, but not DOR(D288A, D293A),
associates with the membrane of LDCVs. Quantitative analysis shows that the immunogold-silver labeling on LDCVs is decreased in cells
expressing the DOR mutant with DOR(263–372) replaced by MOR(283-398) (DOR M2) or DOR(D288A, D293A) (DOR M4) but not with
DOR(R291A, R292A) (DOR M7). The decrease is less pronounced in cells expressing DOR(D288A) (DOR M5). The increase in labeling in
multivesicular bodies is seen in cells expressing DOR M2 and M4. **p < 0.01 versus DOR (mean ± SEM, n = 25 cell profiles/group). Scale
bars, 100 nm.
(D) In contrast to the cell-surface labeling of MOR, the mutated MOR with the third luminal (extracellular) domain of DOR (MOR M1) associates
with vesicles. The MOR mutant with the point-mutated third luminal domain (D288A, D293A) of DOR (MOR M2) is not localized in vesicles.that, when D288A and D293A mutations were intro-
duced into DOR(285–293), mutated MOR exhibited no
LDCV localization (Figures 4A and 4D). Taken together,
these findings strongly support the notion that the third
luminal domain of DOR is both necessary and sufficient
for the LDCV localization.
Direct Interaction of the Substance P Domain
with the Sorting Domain of DOR
The above studies demonstrated that both the sub-
stance P domain of protachykinin and the third luminal
domain of DOR are critical for sorting DORs into
LDCVs. We further inquired whether there is direct
interaction between these two domains. In experi-
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wo proteins CoIP strongly in the cell lysate. However,
he CoIP signal was greatly reduced when a mutated
A-DOR(D288A, D293A) was examined instead of HA-
OR (Figure 5A). In complementary experiments, we
xamined the effect of specific mutation of β-PPT(58–
8) on CoIP with DOR. When positively charged argi-
ine 58 in β-PPT(58–68) was mutated into noncharged
lanine, its CoIP signal with DOR was reduced, and the
eduction was more pronounced with an additional mu-
ation at positively charged lysine 60 (Figure 5B), sug-
esting the importance of electrostatic interaction be-
ween β-PPT(58–68) and DOR. The interaction between
OR(285–293) and the substance P domain was furtherconfirmed in PC12 cells. Following crosslinking with
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625Figure 5. Interaction of the Sorting Domain
of DOR with the Substance P Domain of Pro-
tachykinin
(A) Coimmunoprecipitation (IP) and immu-
noblotting (IB) show that the immunoblot
signal of substance P [β-PPT(58–68)]-GFP
(w30 kDa) is decreased in HA-antibody-pre-
cipitated proteins from HEK293 cells cotrans-
fected with vectors expressing β-PPT(58–68)-
GFP and HA-DOR(D288A, D293A) (DOR M4).
Neither HA-DOR mutant with the C terminus of
MOR (DOR M3) nor DOR(R291A, R292A) (DOR
M7) attenuates the immunoblot signal of
β-PPT(58–68)-GFP. **p < 0.01 versus HA-
DOR (mean ± SEM, n = 3).
(B) The immunoblot signal of β-PPT(58–
68)(R58A)-GFP is weaker than that of β-PPT
(58–68)-GFP in Myc-antibody-precipitated
proteins from HEK293 cells cotransfected
with vectors expressing c-Myc-epitope-
tagged DOR (DOR-Myc) and the peptide-
GFP. β-PPT(58–68)(R58A, K60A) produces a
more pronounced reduction in the signal.
**p < 0.01 versus β-PPT(58–68) (mean ±
SEM, n = 3).
(C) After crosslinking with membrane-per-
meable disuccinimidyl suberate in PC12
cells transfected with the vector expressing
HA-DOR, substance P immunoblot is seen at
the same position as DOR (w60 kDa) in HA-
antibody-precipitated proteins. The signal of
substance P is decreased in cells expressing
HA-DOR(D288A, D293A) (DOR M4) or HA-
DOR mutant with DOR(263–372) replaced by
MOR(283–398) (DOR M2). **p < 0.01 versus
HA-DOR (mean ± SEM, n = 3).
(D) [3H]substance P binds to GST-fused
DOR(281–301), which corresponds roughly
to the third luminal (extracellular) domain,
but not to GST-fused DOR(105–123) and
DOR(184–213), which correspond roughly to
the first and second luminal domain, respec-
tively. [3H]substance P is not bound to the
third luminal domain of DOR with mutation
at D288 and D293. GST protein serves as
control. **p < 0.01 versus GST (mean ± SEM,
n = 9).disuccinimidyl suberate, the amount of endogenous
substance P CoIP with heterologously expressed DOR
(D288A, D293A) was greatly reduced as compared to
that found with HA-DOR (Figure 5C).
More definitive evidence for the direct binding of the
third luminal domain of DOR to the substance P domain
of protachykinin was provided by the pull-down assay
using glutathione S-transferase (GST) fusion peptides.
We found significant [3H]substance P binding with GST-
DOR(281–301) but not with GST-fused DOR(105–123)
and DOR(184–213), two regions roughly corresponding
to the first and second luminal domain, respectively
(Figure 5D). Double-mutation D288A and D293A in GST-
DOR(281–301) disrupted the specific binding with sub-
stance P (Figure 5D). These results indicate that the
sorting domain of DOR directly interacts with the sub-
stance P domain of protachykinin.
Impaired DOR Trafficking in Small DRG Neurons
of PPT-A Knockout Mice
Given that tachykinin plays an essential role in sorting
DOR into the regulated pathway, we further examinedthe effect of PPT-A knockout on the DOR trafficking in
small DRG neurons. Our previous study showed that
the selective DOR agonist deltorphin I (Erspamer et al.,
1989), or the vanilloid-receptor agonist capsaicin, in-
duces the plasma-membrane insertion of LDCV-associ-
ated DORs in these neurons (Bao et al., 2003). However,
in the present study, we found that this agonist-induced
DOR insertion was eliminated in small DRG neurons
from PPT-A knockout mice (Figures 6A and 6B), indicat-
ing that DORs are not present in the regulated pathway.
Small DRG neurons give rise to afferent C fibers that
terminate in laminae I–II in the dorsal horn of the spinal
cord (Figure 6C). Western blotting showed that DOR
was expressed in the dorsal horn of the spinal cord
(Figure 6D). Both immunolabeling and measurements
of agonist binding sites using [3H]deltorphin I (Kitchen
et al., 1997) showed DOR accumulation in laminae I–II
of the spinal cord (Figures 6E and 6F), consistent with
the reports on the presence of DOR in C fiber terminals
(Besse et al., 1992; Fields et al., 1980). However, in lami-
nae I–II of the spinal cord of PPT-A knockout mice, the
DOR level was significantly reduced (Figures 6D–6F).
Cell
626Figure 6. Attenuation of DOR Distribution in Small DRG Neurons of PPT-A Knockout Mice
(A) Dissociated DRG neurons from wild-type (+/+) and PPT-A knockout (−/−) mice are treated with 1 M deltorphin I (Delt) or 1 M capsaicin
for 10 min. Cells are fixed, permeabilized, and immunofluorescence labeled. Confocal images show that deltorphin induces distinct surface-
associated labeling in small DRG neurons (arrow), while the number of intracellular vesicles with the receptor is reduced. The same treatment
does not change DOR distribution in small DRG neurons from PPT-A knockout mice. For semiquantification, the number of small neurons
exhibiting distinct surface-associated DOR labeling in the surface zone (1.5 m in width) (Bao et al., 2003) (arrow-pointed neurons) is counted.
**p < 0.01 versus control (mean ± SEM, n = 200 neuron profiles/group). Scale bar, 5 m.
(B) Cell-surface biotinylation/immunoblotting shows that 10 min treatment of 1 M deltorphin or capsaicin increases surface insertion of DOR
in DRG neurons from wild-type mice but not in DRG neurons from PPT-A knockout mice. *p < 0.05, DOR signal relative to actin of treated
group versus that of control (mean ± SEM, n = 3).
(C) Small DRG neurons give rise to C fibers. Peripheral terminals of C fibers in the skin are activated by nociceptive stimulation, leading to
the release of neurotransmitters at the central terminii in laminae I–II of the spinal cord.
(D) Immunoblotting shows that the DOR level is reduced in the dorsal horn of the spinal cord of PPT-A knockout mice. *p < 0.05 versus the
wild-type (mean ± SEM, n = 3).
(E) Immunofluorescence labeling of DOR is decreased in laminae I–II of the spinal cord of PPT-A knockout mice. Scale bar, 50 m.
(F) Quantitative autoradiographic analysis of [3H]deltorphin I binding shows that DOR binding sites in laminae I–II of the spinal cord of PPT-A
knockout mice is significantly decreased compared with that in the spinal cord of wild-type mice. **p < 0.01 versus the wild-type (mean ±
SEM, n = 3).
(G) Pre-embedding immunogold-silver labeling shows that, in the axonal terminals in lamina II of the spinal cord of PPT-A knockout mice,
DOR is seen in endosome-like vesicles (arrowhead), while LDCVs (arrows) are not labeled. **p < 0.01 versus the wild-type (mean ± SEM, n =
18 terminals). Scale bar, 100 nm.
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627This reduction in DOR is specific since the immuno-
labeling of MORs and γ-aminobutyric acid B-receptor
subunit 2 in these laminae was not changed (Figure S4).
At the ultrastructural level, we found that DORs were
not associated with LDCVs in the axonal terminals in
lamina II of the spinal cord of these mice but with some
lucent endosome-like vesicles (Figure 6G), suggesting
that the reduction in the DOR level may be due to the
decrease in the DOR transport via LDCVs.
Importance of DOR Sorting for Spinal Analgesia
The functional importance of DOR sorting to the regu-
lated pathway was further examined by studying spinal
DOR-mediated analgesia. The DORs in C fiber ter-
minals are known to be involved in analgesia at the spi-
nal-cord level (Bilsky et al., 2000; Labuz et al., 1998;
Zhu et al., 1999). Using the tail-immersion test in which
brief immersion of the tail in 52°C water generates a
mildly nociceptive stimulus, we found that tail-flick
latency did not differ between wild-type and PPT-A
knockout mice (Figure 7A), consistent with a previous
report (Zimmer et al., 1998). We observed that intrathe-
cal injection of DOR-selective agonist deltorphin I in-
duced analgesic responses in a dose- and time-depen-Figure 7. Loss of DOR-Mediated Spinal Anal-
gesia and Morphine Tolerance in PPT-A
Knockout Mice
(A) In the 52°C water tail-immersion test, no
significant difference of the tail-flick latency
between PPT-A knockout (−/−) and wild-type
(+/+) mice is detected (mean ± SEM, n = 20).
(B) In the 52°C water tail-immersion test, in-
trathecal (i.t.) injection of deltorphin I (Delt)
causes an increase in tail-flick latency in a
dose- and time-dependent manner in wild-
type mice but not in PPT-A knockout mice
(mean ± SEM, n = 8). A maximum score is
assigned (100%) to animals not responding
within 10 s. M.P.E., maximum possible effect.
*p < 0.05 and **p < 0.01 versus the effect of
the same dose in wild-type mice.
(C) Intrathecal injection of morphine and
baclofen (30 min) causes an increase in tail-
flick latency in a dose-dependent manner in
both wild-type and PPT-A knockout mice
(mean ± SEM, n = 8) in the 52°C water tail-
immersion test. In PPT-A knockout mice, a
lower dose of morphine is needed to pro-
duce antinociception equivalent to that in
wild-type mice. *p < 0.05 and **p < 0.01 ver-
sus the effect of the same dose in wild-type
mice.
(D) In wild-type mice, morphine tolerance is
demonstrated by the loss of the analgesic
response to daily subcutaneous administra-
tion (s.c.) of 5 mg morphine/kg within 5 days.
The PPT-A knockout mice (mean ± SEM, n =
20) do not develop the tolerance following
the same treatment of morphine for 10 days.
Analgesia is tested 30 min after morphine
administration with tail-flick assay.dent manner in wild-type mice (Figure 7B). However, in
PPT-A knockout mice, this DOR-mediated analgesia
was abolished (Figure 7B). This effect is specifically
caused by DOR deficiency rather than a nonspecific
reduction of the responsiveness of the knockout
mice because dose-dependent spinal analgesia was in-
duced in these mice by intrathecal injection of mor-
phine, which primarily acts on MORs, and by a low
dose of the γ-aminobutyric acid B-receptor agonist
baclofen (Figure 7C) (Hylden and Wilcox, 1980; Wilson
and Yaksh, 1978). In PPT-A knockout mice, intrathecal
morphine-induced analgesia was in fact enhanced (Fig-
ure 7C). The median effective dose (ED50) for morphine
analgesia was significantly lower [ED50 = 0.09 g, with
95% confidence limits (0.04–0.22 g)] than that in wild-
type mice [ED50 = 0.40 g, (0.24–0.70 g)]. Thus, spinal
DOR-mediated analgesia was specifically impaired in
PPT-A knockout mice.
Interestingly, we found that morphine tolerance was
absent in PPT-A knockout mice (Figure 7D). This is in
sharp contrast to wild-type mice, in which the analgesic
response to daily subcutaneous administration of mor-
phine (5 mg/kg) was lost within 5 days (Figure 7D). After
10 days of chronic morphine administration, cumulative
Cell
628dose-response curves showed a significant 3.7-fold
shift to the right of the morphine ED50 in wild-type mice,
while the potency of morphine in PPT-A knockout mice
remained unchanged (Table S1). These data are consis-
tent with previous reports that mice lacking DOR or its
endogenous ligand enkephalin do not develop analge-
sic tolerance to morphine (Nitsche et al., 2002; Zhu et
al., 1999). This suggests that the DORs sorted into
LDCVs by protachykinin are involved in the develop-
ment of morphine tolerance.
Discussion
The present study demonstrates a link between the
tachykinin and opioid systems that are involved in
modulation of pain transmission in the spinal cord. We
found that, in small DRG neurons, sorting of DORs into
the regulated pathway requires preprotachykinin ex-
pression. The sorting domain was found to locate
within the third luminal domain of DOR, and its interac-
tion with the substance P domain of protachykinin was
essential for sorting DORs into LDCVs (see model in
Figure 8). This sorting of DORs allows regulated inser-
tion of DORs in response to nociceptive stimuli. Our
findings delineate not only a molecular mechanism for
selective sorting of a specific cell-surface receptor into
the regulated pathway but also the cell biological basis
for the modulation of opioid analgesia, including DOR-
mediated analgesia and morphine tolerance.
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cellular) domain (green region) of DOR with the substance P do-
main of protachykinin leads to sorting DOR into LDCVs. A limited
number of DORs are transported in the constitutive pathway. The
stimulation triggers Ca2+ influx that induces insertion of LDCV-
associated DORs (Bao et al., 2003).
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Dssential Role of the Substance P Domain
n Protachykinin for DOR Sorting
n this study, the importance of protachykinin for DOR
orting was first suggested by the finding that LDCV
ocalization of DORs was absent in small DRG neurons
rom PPT-A knockout mice. This requirement of PPT
or DOR sorting was further confirmed by heterologous
oexpression of β-PPT with DOR in HEK293 cells in
hich LDCVs were reconstituted by coexpression of
hromogranin A. Interestingly, coexpression of DOR
ith a mutated α-CGRP in which the CGRP domain
as substituted with the substance P domain resulted
n DOR localization in reconstituted LDCVs. Thus, the
ubstance P domain in a different polypeptide environ-
ent provided by another granule content protein
-CGRP is sufficient to convey the localization signal
or DOR. The evidence from CoIP and binding experi-
ents further supports the notion that the substance P
omain interacts directly with the sorting domain of
OR. Thus, during the formation of LDCVs in the trans-
olgi network, protachykinin plays a critical role of pre-
enting the substance P domain for the interaction with
OR, leading to DOR sorting into LDCVs (see model in
igure 8).
The current views about the sorting events in the reg-
lated pathway have been summarized as “sorting for
ntry” and “sorting by retention” (Arvan and Castle,
998; Gorr et al., 2001). We found that DORs were ex-
luded from LDCVs when protachykinin was absent,
uggesting that DOR is sorted into LDCV by selective
ntry (see model in Figure 8). It is possible, however,
hat the interaction with protachykinin may also help
OR retention in LDCVs during the maturation of
DCVs when non-LDCV membrane proteins are re-
oved. Our findings thus nicely illustrate an active
unction of a precursor protein prior to the cleavage
nd generation of mature peptides.
he Sorting Domain of DOR
t is generally assumed that a specific domain of the
rotein is responsible for its sorting into distinct path-
ays (Arvan and Castle, 1998; Kelly, 1985; Tooze et al.,
001). Sorting domains are identified in some regulated
ecretory proteins, such as pro-opiomelanocortin (Cool
t al., 1995, 1997), and in a few granule membrane pro-
eins, such as P-selectin and pancreatic GP-2 (Arvan
nd Castle, 1998). In the present study, extensive do-
ain-swap and point-mutation experiments led to the
dentification of the third luminal domain of DOR as the
ritical site for the interaction with the substance P do-
ain contained within protachykinin. This interaction
ppears to be markedly influenced by electrostatic
orces since point mutation of charged residues within
he interacting domain abolished the interaction.
Interestingly, the third luminal domain of DOR also me-
iates DOR/agonist binding. The amino acids I289, R291,
292, V296, V297, and L300, within or near the sequence
285–293), are involved in selective binding of δ-opioids
Decaillot et al., 2003; Meng et al., 1996; Pepin et al., 1997;
arga et al., 1996; Wang et al., 1995). We found that D288
nd D293 but not R291 and R292 were critical for sorting
ORs into LDCVs. Thus, distinct amino acids are involved
n different functions of this multifunctional domain. Our
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629recent experiments also showed that substance P did not
bind DOR expressed on the surface of HEK293 cells (data
not shown). Thus, the mechanism of DOR/protachykinin
interaction may differ from that of receptor/agonist bind-
ing on the cell surface.
Regulated Sorting of Cell-Surface Receptors
It is generally believed that the constitutive pathway is
the normal trafficking route for cell-surface receptors.
Our results demonstrate a mechanism by which gran-
ule contents may serve to sort surface receptors into
the regulated pathway by selective interaction with the
luminal domain of the receptor. In DRG neurons of PPT-A
knockout mice, DORs excluded from LDCVs appeared
to be sorted into the degradation pathway. It is possible
that the relative amount of surface receptors sorted into
the regulated versus constitutive/degradation path-
ways can be modulated by the expression of a particu-
lar granule-content molecule that interacts with the
receptor. This mechanism would allow the surface ex-
pression of a specific receptor to be modulated by
physiological or pathological stimulation.
Functional Implications
Following nociceptive stimulation, substance P is re-
leased from the central terminals of C fibers and acti-
vates its receptor on dorsal spinal-cord neurons (Man-
tyh et al., 1995; Woolf and Salter, 2000). Previous studies
have shown that PPT-A knockout mice do not show
significant change in spinal nociceptive response (Cao
et al., 1998; Zimmer et al., 1998). However, in the pres-
ent study, we found that these mice showed marked
deficiency in DOR-mediated analgesia. This is due to
impaired sorting of DORs into the regulated pathway
and reduced axonal transport of DORs in C fibers. Pro-
tachykinin-dependent sorting of DORs is essential for
the action of DORs in the spinal cord.
Recent studies suggest that DORs are involved in
modulation of MOR functions in the spinal cord since
DORs interact with MORs in the cell membrane and
blockade of DORs enhances MOR-mediated spinal an-
algesia (Gomes et al., 2004; Schiller et al., 1999). Our
finding that spinal morphine analgesia was enhanced
in PPT-A knockout mice suggests that MOR functions
may be modulated by regulated DOR insertion into the
plasma membrane. Moreover, consistent with the no-
tion that DOR is required for morphine tolerance (Zhu
et al., 1999), we found that morphine tolerance was not
developed when stimulus-induced surface insertion of
DORs was eliminated in PPT-A knockout mice. These
findings further strengthen the functional role of pro-
tachykinin-dependent sorting of DORs in opioid analge-
sia. Protachykinin is not only essential for DOR-mediated
analgesia but is also involved in the regulation of MOR-
mediated analgesia and the development of morphine
tolerance.
Tachykinin and opioid systems, two major regulatory
systems of pain transmission in the spinal cord, are
now directly linked by DOR/protachykinin interaction
shown in the present study. Thus, changes in tachykinin
expression may lead to modulation of opioid actions in
physiological or pathological conditions. In fact, tachyki-
nin expression in small DRG neurons is upregulated byperipheral inflammation and downregulated by periph-
eral nerve injury (Woolf and Salter, 2000). Our results
provide the groundwork for further analysis of the mod-
ulation of opioid analgesia associated with the regula-
tion of tachykinin expression in different pain states.
Experimental Procedures
Immunochemistry
The mice and cultured cells were fixed and immunofluorescence
labeled according to our previous protocol (Bao et al., 2003). The
procedure and antibodies are described in the Supplemental Data.
Electron Microscopy
Five adult male mice, five PPT-A knockout mice, and transfected
cells were processed for pre-embedding immunogold-silver label-
ing (Zhang et al., 1998a) and/or postembedding labeling (Bao et al.,
2003). The percentage of DOR and/or substance P in LDCVs was
counted in small-neuron profiles. Numbers of LDCVs/m2 and
gold-silver particles associated with several subcellular structures
were quantified (mean ± SEM and unpaired t test).
Plasmid Construction
Mouse DOR (Kieffer et al., 1992), rat MOR (Thompson et al., 1993),
and neuropeptide Y Y1 receptor (Eva et al., 1990) were subcloned
into pCMV-HA vector. The DOR with point mutation and DOR/MOR
or Y1 receptor chimeras were constructed with a two-round PCR
method and cloned into pCMV-HA or pCMV-Myc vector. Mouse
β-PPT(1–130), β-PPT(1–68) (Chiwakata et al., 1991), β-PPT(1–57,
69–130), α-CGRP(1–82)/β-PPT(58–68), and α-CGRP(1–119) with the
signal peptides were cloned into pcDNA3.1 or pEGFP-N3 vector.
β-PPT(58–68), β-PPT(58–68)(R58A), β-PPT(58–68)(R58A, K60A), and
α-CGRP(83–119) without the signal peptides were cloned into
pEGFP-N3 vector. Rat chromogranin A was cloned into pEGFP-N1
vector. Detailed procedures and PCR primers are described in the
Supplemental Data.
Cell Culture and Transfection
PC12 cells (ATCC) and dissociated mouse DRG neurons, cultured
in DMEM (GIBCO) containing 10% fetal bovine serum, were trans-
fected with 1 g plasmid/5 l Lipofectin reagent (GIBCO)/35 mm
dish in serum-free medium for 20 hr and then in the medium con-
taining serum for 4–5 days. HEK293 cells (ATCC), cultured in MEM
(GIBCO) containing 10% fetal bovine serum, were transfected with
1–2 g plasmid/60 mm dish and CellPhect Transfection Kit (Amer-
sham Pharmacia). Transfected cells were cultured for 2–3 days.
Immunoprecipitation
Cells were lysed in ice-cold RIPA buffer (150 mM NaCl, 30 mM
HEPES, 10 mM NaF, 1% Triton, 0.01% SDS). For crosslinking that
is needed to detect associated small peptide in the cell, PC12 cells
and dissociated DRG neurons were resuspended in PBS (pH 7.5)
with 100 nM disuccinimidyl suberate for 30 min at RT before lysis.
The suspended lysate was immunoprecipitated with 0.5 g mouse
anti-HA antibody (Boehringer Mannheim), mouse anti-GFP anti-
body (Roche), rabbit anti-DOR antibody (Santa Cruz), or anti-sub-
stance P antibody (Santa Cruz) for 1 hr at 4°C and then with protein
A for rabbit antibody or protein G for mouse antibody overnight at
4°C. Immunoprecipitates were collected and resuspended in RIPA
buffer without SDS, washed at least three times, and then incu-
bated in SDS sample buffer for 30 min at 60°C. Five percent of total
lysate or supernatant after IP and half of the immunoprecipitated
proteins were loaded. Immunoblotting was processed and semiqu-
antified (mean ± SEM and unpaired t test). Normalized CoIP effi-
ciency of A with B (%) = 100 × [(A in the lysate − A in the superna-
tant after IP)/A in the lysate]/[(B in the lysate − B in the supernatant
after IP)/B in the lysate].
GST Pull-down and [H3]Substance P Binding
Different DOR fragments were cloned into pGEX plasmid. GST-
fused proteins were expressed and purified with glutathione-Seph-
arose beads, and equal amounts of proteins were immobilized by
Cell
630incubating with glutathione beads prewashed with TEN100 (20 mM
Tris [pH 7.4], 0.1 mM EDTA, and 100 mM NaCl). The products were
equilibrated in TEN100 for 1 hr at 4°C. Twenty microliters of sub-
stance P mixture containing 10−7 M [H3]substance P (Amersham
Pharmacia) and 10−5 M substance P was incubated with 10 l im-
mobilized GST-fused protein in 170 l 0.1 M NaH2PO4 buffer (pH
5.6) for 3 hr at 4°C. The beads were washed with 300 l TEN buffer.
Radioactivity of the bound [3H]substance P was determined by a
scintillation counter and analyzed (mean ± SEM and unpaired t
test).
Cell-Surface Biotinylation and Western Blotting
According to our previous protocol (Bao et al., 2003), biotinylation
of neurons was carried out at 37°C for 10 min in the presence of 1
M deltorphin or capsaicin followed by biotinylation at 4°C for 45
min. Mouse DRG and the dorsal spinal cord were sonicated/
homogenized and centrifuged. The samples were loaded on SDS-
PAGE, transferred, probed with antibodies, and visualized with en-
hanced chemiluminescence. Antibodies against DOR (1:3,000),
substance P (1:1,000), HA (1:1,000), Myc (1:1000), GFP (1:3,000),
and actin (1:10,000) were used. Immunoblot was analyzed with NIH
image program (mean ± SEM and unpaired t test).
Receptor Autoradiography
Cryosections of lumbar spinal cord were processed for [3H]deltor-
phin I (Zeneca) binding, according to our previous protocol (Kitchen
et al., 1997). The procedure and analysis are described in the Sup-
plemental Data.
Analgesia Tests
Experiments complied with the policy of the Society for Neurosci-
ence (USA) on the use of animals. Antinociception was assessed
using 52°C water tail-flick test. The latency to the first sign of a
rapid tail-flick was taken as the behavioral endpoint. Each mouse
was tested for baseline latency. The test compound dissolved in 5
l vehicle was administrated via lumbar puncture (Hylden and Wil-
cox, 1980). A maximum score was assigned (100%) to animals not
responding within 10 s. Antinociception was calculated by the for-
mula: % maximum possible effect = 100 × (test latency − baseline
latency)/(10 − baseline latency). Single-dose data were analyzed with
one-way ANOVA and t test for group comparisons (mean ± SEM).
Groups of mice were used to determine ED50 values of morphine
analgesia following intrathecal or subcutaneous administration of
morphine. Analgesia was defined as a doubling or greater of the
baseline latency for an individual mouse. ED50 values of morphine
and their 95% confidence limits were determined with the Bliss
program. For chronic morphine treatment, ED50 was determined 10
days after daily treatment of morphine (5 mg/kg, s.c.) with a cumu-
lative dose-response paradigm.
Supplemental Data
Supplemental Data include Supplemental Experimental Proce-
dures, one table, and four figures and can be found with this article
online at http://www.cell.com/cgi/content/full/122/4/619/DC1/.
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